Skip to content

Study · Non-randomized trial · n = 37 · 2015

4 results

Comparison of dienogest versus triptorelin acetate in premenopausal women with adenomyosis: a prospective clinical trial.

Fawzy M, Mesbah Y

Archives of gynecology and obstetrics20 May 2015Cited by 42 (Europe PMC)

PMID25990480 (opens in a new tab)DOI10.1007/s00404-015-3755-5 (opens in a new tab)PepBankPUB-25990480
Publisher pagePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In premenopausal women with adenomyosis, pelvic pain reductions with triptorelin and dienogest were equivalent after 16 weeks.

    In plain wordsIn women with adenomyosis, triptorelin and dienogest produced equivalent pain reductions after 16 weeks.

    Peptide
    Triptorelin (Trelstar, Decapeptyl)
    Outcome
    No significant changePelvic pain equivalence versus dienogest
    Study

    n = 37

    Comparator
    Dienogest
    Outcome group
    Pain · Reproductive and sexual health
    Studied dose
    3.75 mg every 4 weeks · subcutaneous · 16 weeksAs given in this study (human).

    Source sentences

    Summary
    Significant reductions in pelvic pains after 16 weeks treatment were obtained in both groups demonstrating the equivalence of dienogest relative to triptorelin acetate.
    2 context sentences
    Summary · context
    A total of 41 patients with adenomyosis suffering from pelvic pains and menorrhagia were recruited.
    Summary · context
    First group was managed with oral dienogest (2 mg/day, orally) while the second group received triptorelin acetate (3.75 mg/4 weeks, subcutaneous injection) for 16 weeks.
  2. 02HumanNon-randomized trialEfficacy outcome

    In premenopausal women with adenomyosis, triptorelin controlled menorrhagia more effectively than dienogest.

    In plain wordsIn women with adenomyosis, triptorelin controlled heavy menstrual bleeding better than dienogest.

    Peptide
    Triptorelin (Trelstar, Decapeptyl)
    Outcome
    DecreaseMenorrhagia control
    Study

    n = 37

    Comparator
    Dienogest
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    3.75 mg every 4 weeks · subcutaneous · 16 weeksAs given in this study (human).

    Source sentences

    Summary
    Triptorelin acetate was more effective in controlling of menorrhagia and reduction of uterine volume.
    2 context sentences
    Summary · context
    A total of 41 patients with adenomyosis suffering from pelvic pains and menorrhagia were recruited.
    Summary · context
    First group was managed with oral dienogest (2 mg/day, orally) while the second group received triptorelin acetate (3.75 mg/4 weeks, subcutaneous injection) for 16 weeks.
  3. 03HumanNon-randomized trialEfficacy outcome

    In premenopausal women with adenomyosis, triptorelin reduced uterine volume more effectively than dienogest.

    In plain wordsIn women with adenomyosis, triptorelin reduced uterus size more than dienogest.

    Peptide
    Triptorelin (Trelstar, Decapeptyl)
    Outcome
    DecreaseUterine volume reduction
    Study

    n = 37

    Comparator
    Dienogest
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    3.75 mg every 4 weeks · subcutaneous · 16 weeksAs given in this study (human).

    Source sentences

    Summary
    Triptorelin acetate was more effective in controlling of menorrhagia and reduction of uterine volume.
    2 context sentences
    Summary · context
    A total of 41 patients with adenomyosis suffering from pelvic pains and menorrhagia were recruited.
    Summary · context
    First group was managed with oral dienogest (2 mg/day, orally) while the second group received triptorelin acetate (3.75 mg/4 weeks, subcutaneous injection) for 16 weeks.
  4. 04HumanNon-randomized trialOther

    Among women with adenomyosis allocated to triptorelin, 18 (94.7%) completed the trial.

    In plain wordsAmong women with adenomyosis assigned triptorelin, 18 (94.7%) completed the trial.

    Peptide
    Triptorelin (Trelstar, Decapeptyl)
    Outcome
    Not applicableTrial completion
    Study

    n = 19

    Outcome group
    Treatment adherence and retention · Whole body
    Studied dose
    3.75 mg every 4 weeks · subcutaneous · 16 weeksAs given in this study (human).

    Measurements

    Completed trial
    18 patients
    triptorelin acetate group (n=19)
    Completion rate
    94.7%
    triptorelin acetate group

    Source sentences

    Summary
    A total of 41 women were allocated to treatment with dienogest (n = 22) or triptorelin acetate (n = 19); 19 (86.4 %) and 18 (94.7 %) % of the respective groups completed the trial.
    2 context sentences
    Summary · context
    A total of 41 patients with adenomyosis suffering from pelvic pains and menorrhagia were recruited.
    Summary · context
    First group was managed with oral dienogest (2 mg/day, orally) while the second group received triptorelin acetate (3.75 mg/4 weeks, subcutaneous injection) for 16 weeks.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.